Natacha Omer

Dr. Natacha Omer

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LLLoretta Lau
Loretta Lau
DKDong-Anh Khuong-Quang
Dong-Anh Khuong-Quang
CMChelsea Mayoh
Chelsea Mayoh
MWMarie Wong
Marie Wong
PBPaulette Barahona
Paulette Barahona
DZDavid Ziegler
David Ziegler
Recent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT). Here we report consecutive data from 384 patients with high-risk pediatric cancer (with an expected cure rate of less than 30%) who had at least 18 months of follow-up on the ZERO Childhood Cancer Precision Medicine Program PRecISion Medicine for Children with Cancer (PRISM) trial. A total of 256 (67%) patients received PGT recommendations and 110 (29%) received a recommended treatment. PGT resulted in a 36% objective response rate and improved 2-year progression-free survival compared with standard of care (26% versus 12%; P = 0.049) or targeted agents not guided by molecular findings (26% versus 5.2%; P = 0.003). PGT based on tier 1 evidence, PGT targeting fusions or commenced before disease progression had the greatest clinical benefit. Our data show that PGT informed by comprehensive molecular profiling significantly improves outcomes for children with high-risk cancers. ClinicalTrials.gov registration: NCT03336931

1 April 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
NONatacha Omer
Natacha Omer
MDMarie Cécile Le Deley
Marie Cécile Le Deley
SPSophie Piperno-Neumann
Sophie Piperno-Neumann
PMPerrine Marec-Berard
Perrine Marec-Berard
AIAntoine Italiano
Antoine Italiano
NGNathalie Gaspar
Nathalie Gaspar

20 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Rachael Louise TerryRachael Louise Terry
Rachael Louise Terry
DMDeborah Meyran
Deborah Meyran
EFEmmy D.G. Fleuren
Emmy D.G. Fleuren
CMChelsea Mayoh
Chelsea Mayoh
JZJoe Zhu
Joe Zhu
PEPaul Ekert
Paul Ekert
Sarcomas are a diverse group of bone and soft tissue tumors that account for over 10% of childhood cancers. Outcomes are particularly poor for children with refractory, relapsed, or metastatic disease. Chimeric antigen receptor T (CAR T) cells are an exciting form of adoptive cell therapy that potentially offers new hope for these children. In early trials, promising outcomes have been achieved in some pediatric patients with sarcoma. However, many children do not derive benefit despite significant expression of the targeted tumor antigen. The success of CAR T cell therapy in sarcomas and other solid tumors is limited by the immunosuppressive tumor microenvironment (TME). In this review, we provide an update of the CAR T cell therapies that are currently being tested in pediatric sarcoma clinical trials, including those targeting tumors that express HER2, NY-ESO, GD2, EGFR, GPC3, B7-H3, and MAGE-A4. We also outline promising new CAR T cells that are in pre-clinical development. Finally, we discuss strategies that are being used to overcome tumor-mediated immunosuppression in solid tumors; these strategies have the potential to improve clinical outcomes of CAR T cell therapy for children with sarcoma.

30 November 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
EFEmmy D.G. Fleuren
Emmy D.G. Fleuren
Rachael Louise TerryRachael Louise Terry
Rachael Louise Terry
DMDeborah Meyran
Deborah Meyran
NONatacha Omer
Natacha Omer
JTJoseph A. Trapani
Joseph A. Trapani
PEPaul Ekert
Paul Ekert
Despite aggressive surgery, chemotherapy, and radiotherapy, survival of children and adolescents and young adults (AYAs) with sarcoma has not improved significantly in the past four decades. Immune checkpoint inhibitors (ICIs) are an exciting type of immunotherapy that offer new opportunities for the treatment of paediatric and AYA sarcomas. However, to date, most children do not derive a benefit from this type of treatment as a monotherapy. The immunosuppressive tumour microenvironment is a major barrier limiting their efficacy. Combinations of ICIs, such as anti-PD-1 therapy, with targeted molecular therapies that have immunomodulatory properties may be the key to breaking through immunosuppressive barriers and improving patient outcomes. Preclinical studies have indicated that several receptor tyrosine kinase inhibitors (RTKi) can alter the tumour microenvironment and boost the efficacy of anti-PD-1 therapy. A number of these combinations have entered phase-1/2 clinical trials, mostly in adults, and in most instances have shown efficacy with manageable side-effects. In this review, we discuss the status of ICI therapy in paediatric and AYA sarcomas and the rationale for co-treatment with RTKis. We highlight new opportunities for the integration of ICI therapy with RTK inhibitors, to improve outcomes for children with sarcoma.

3 October 2023 in Research Square
Verified
Preprint
Open access
PDF file
DZDavid Ziegler
David Ziegler
LLLoretta Lau
Loretta Lau
DKDong-Anh Khuong-Quang
Dong-Anh Khuong-Quang
MWMarie Wong
Marie Wong
PBPaulette Barahona
Paulette Barahona
NONatacha Omer
Natacha Omer
Recent reports have shown that precision medicine can identify new treatment strategies for childhood cancer patients. However, it remains unclear which patients will benefit most from precision-guided treatment (PGT). Here we report 384 consecutive high-risk childhood cancer patients (with an expected cure rate of <30%) who had at least 18 months of follow-up on the ZERO Childhood Cancer Program PRISM trial. A total of 256 (67%) patients received PGT recommendations, of whom 110 (43%) received a recommended treatment. PGT resulted in a 36% objective response rate and improved 2-year progression-free survival compared with standard of care (26% vs. 12%; P=0.049) or targeted agents not guided by molecular findings (26% vs. 5.2%; P=0.003). PGT based on Tier 1 evidence, PGT targeting fusions or commenced prior to disease progression had the greatest clinical benefit. Our data show that PGT informed by comprehensive molecular profiling significantly improves outcomes for children with high-risk cancers.

17 July 2025 in Journal of Paediatrics and Child Health
Verified
Journal Article
Open access
TRTrisha A. Soosay Raj
Trisha A. Soosay Raj
NONatacha Omer
Natacha Omer
AGAmy Gray
Amy Gray
Aim: Despite ward rounds being fundamental to hospital‐based clinical training, the reported educational value is low. Especially in busy environments, missed learning opportunities occur due to implicit learning, time barriers, and lack of ward round structure. The STIC framework ( S et, T arget, I nspect, Close ) provides a learner‐centred, structured approach to ward round teaching, aimed to enhance education within limited timeframes. We aimed to investigate how the introduction of the STIC framework impacts on learner‐centred teaching within a tertiary Paediatric Oncology department. Methods: A mixed‐methods approach was used to evaluate framework implementation, with two participant groups comprising 16 junior and senior doctors over 3 months. Surveys were used to document junior staff experience on rounds pre‐ and post‐implementation, with focus groups and interviews used for all participants to explore satisfaction and attitudes to the tool. Results: Learner satisfaction improved across all domains of the framework, specifically opportunities for leading clinical encounters and learning on consultant‐led rounds. Despite consultants reporting lack of uptake, trainees reported improved teaching. Consultant beliefs and enthusiasm had a strong impact on trainee satisfaction. Trainees placed a high value on active participation and autonomy for their learning. Factors distinct to teaching were reported to affect learner satisfaction, such as planning, time management, and departmental culture. Conclusions: We demonstrate enhanced teaching despite poor perceived uptake, demonstrating the potential of the STIC framework with further implementation. Our study also highlights that in addition to a specific teaching focus, consultant engagement and a safe clinical learning environment are crucial for learning.